Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

MLA

Alison C. Johnson, et al. “Haemoglobin Level Increase as an Efficacy Biomarker during Axitinib Treatment for Metastatic Renal Cell Carcinoma: A Retrospective Study.” BMC Cancer, vol. 17, no. 1, May 2017, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s12885-017-3312-7.

APA

Alison C. Johnson, Margarida Matias, Helen Boyle, Bernard Escudier, Alicia Molinier, Brigitte Laguerre, Carole Helissey, Pierre-Emmanuel Brachet, Audrey Emmanuelle Dugué, Loic Mourey, Elodie Coquan, & Florence Joly. (2017). Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study. BMC Cancer, 17(1), 1–8. https://doi.org/10.1186/s12885-017-3312-7

Chicago

Alison C. Johnson, Margarida Matias, Helen Boyle, Bernard Escudier, Alicia Molinier, Brigitte Laguerre, Carole Helissey, et al. 2017. “Haemoglobin Level Increase as an Efficacy Biomarker during Axitinib Treatment for Metastatic Renal Cell Carcinoma: A Retrospective Study.” BMC Cancer 17 (1): 1–8. doi:10.1186/s12885-017-3312-7.